CXCL9 and tuberculosis: Here, results based on screening cohort blood plasma levels of a set of cytokines and chemokines demonstrated that MTB antigen-specific CXCL9 assays could be used to compensate for low IGRA diagnostic accuracy, which occurs when IGRA results obtained for active TB cases are negative; meanwhile, sensitivities of both assays were comparable when used to diagnose active TB patients with positive IGRA results.